Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 5/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | SLC6A11 | P48066 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.45 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6007677 | 1.00 | SLC6A1 (0.46) | SLC6A1BTKCACNA1HSLC6A11MEN1 | |
| SCHEMBL26128032 | 0.93 | MEN1 (0.47) | SLC6A1BTKMEN1KMT2ADRD2 | |
| SCHEMBL13635148 | 0.84 | DRD2 (0.48) | CACNA1HMEN1KMT2AEPHX1DRD2 | |
| SCHEMBL14599656 | 0.84 | CACNA1H (0.47) | CACNA1HMEN1KMT2AEPHX1DRD2 | |
| SCHEMBL13635147 | 0.84 | CACNA1H (0.47) | CACNA1HMEN1KMT2AEPHX1DRD2 | |
| SCHEMBL24811481 | 0.84 | CACNA1H (0.52) | BTKCACNA1HMEN1KMT2AEPHX1 | |
| SCHEMBL18233688 | 0.82 | DRD2 (0.46) | CACNA1HMEN1KMT2AEPHX1DRD2 | |
| SCHEMBL32690155 | 0.81 | DRD2 (0.47) | CACNA1HMEN1KMT2AEPHX1DRD2 | |
| SCHEMBL24172673 | 0.80 | DRD2 (0.56) | CACNA1HMEN1KMT2AEPHX1DRD2 | |
| SCHEMBL4024516 | 0.80 | DRD2 (0.56) | CACNA1HMEN1KMT2AEPHX1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084807-A1 | Novel denzamide derivatives and process for production thereof | ASTELLAS PHARMA INC. (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084807-A1 | Novel denzamide derivatives and process for production thereof | NNMT, SCN5A, QDPR | SLC6A1 316/4885BTK 1779/4885CACNA1H 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.